SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...

Severe Hypoglycemia Ups Cardiovascular Risk in Diabetes Two studies demonstrate no difference versus placebo for saxagliptin, alogliptin. For patients with type 2 diabetes, treatment with the ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...

The American College of Physicians issued new guidelines for Type 2 diabetes treatment, which for the first time recommends the use of GLP-1s and another class of diabetes drugs called SGLT-2s ...

Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).

GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 ...

With regards to his pioglitazone use, he had no history of heart failure, and his ALT level was acceptable at the time of discharge at 25 U/L. Signs and symptoms of heart failure were reviewed with ...

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...